Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Employees

907

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-10-29 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Quotes

Date	Price	Change	Volume
24-09-09	130.88 $	+1.24%	127,841
24-09-06	129.28 $	+0.72%	719,359
24-09-05	128.35 $	-1.88%	624,136
24-09-04	130.81 $	-1.65%	385,441
24-09-03	133.00 $	-0.66%	626,208

Delayed Quote Nyse, September 06, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

129.28USD

Average target price

136.33USD

Spread / Average Target

+5.46%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 01:31:44 2024-09-09 pm EDT			5-day change	1st Jan Change
131.10 ^USD	+1.40%		-1.54%	+64.74%

Sep. 05	Transcript : Glaukos Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 12:20 PM
Aug. 27	Needham Raises Price Target on Glaukos to $149 From $137, Maintains Buy Rating	MT

Capitalization	7.1B	P/E ratio 2024 *	-46x	P/E ratio 2025 *	-82.7x
Enterprise value	7.28B	EV / Sales 2024 *	19.5x	EV / Sales 2025 *	15.7x
Free-Float	96.75%	Yield 2024 *	-	Yield 2025 *	-

Transcript : Glaukos Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 12:20 PM	Sep. 05
Needham Raises Price Target on Glaukos to $149 From $137, Maintains Buy Rating	Aug. 27	MT
Glaukos Insider Sold Shares Worth $646,791, According to a Recent SEC Filing	Aug. 23	MT
Truist Adjusts Glaukos' Price Target to $145 From $141, Keeps Buy Rating	Aug. 01	MT
Needham Adjusts Glaukos' Price Target to $137 From $131, Keeps Buy Rating	Aug. 01	MT
Glaukos Narrows Q2 Non-GAAP Loss as Net Sales Increase	Aug. 01	MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q2 Revenue $95.7M, vs. Street Est of $88.9M	Jul. 31	MT
Transcript : Glaukos Corporation, Q2 2024 Earnings Call, Jul 31, 2024	Jul. 31
Glaukos Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Jul. 31	CI
Glaukos Corporation Raises Net Sales Guidance for 2024	Jul. 31	CI
Truist Raises Price Target on Glaukos to $141 From $125, Maintains Buy Rating	Jul. 16	MT
Morgan Stanley Raises Price Target on Glaukos to $120 From $100, Keeps Equalweight Rating	Jul. 15	MT
Citigroup Downgrades Glaukos to Neutral From Buy, Lifts Price Target to $132 From $130	Jul. 10	MT

Needham Raises Price Target on Glaukos to $149 From $137, Maintains Buy Rating	Aug. 27	MT
Truist Adjusts Glaukos' Price Target to $145 From $141, Keeps Buy Rating	Aug. 01	MT
Needham Adjusts Glaukos' Price Target to $137 From $131, Keeps Buy Rating	Aug. 01	MT
Truist Raises Price Target on Glaukos to $141 From $125, Maintains Buy Rating	Jul. 16	MT
Morgan Stanley Raises Price Target on Glaukos to $120 From $100, Keeps Equalweight Rating	Jul. 15	MT

Glaukos Corporation Stock

Equities

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Valuation: Glaukos Corporation

Chart: Glaukos Corporation

Latest news: Glaukos Corporation

Last Transcript: Glaukos Corporation

Analysts' recommendations: Glaukos Corporation

Press Releases: Glaukos Corporation

News in other languages: Glaukos Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Glaukos Corporation

ETFs: Glaukos Corporation

Medical Devices & Implants

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Glaukos Announces Participation in Upcoming Investor Conferences	Aug. 19	AQ
Glaukos Announces Participation in Upcoming Investor Conferences	Aug. 16	BU
Glaukos : Investor Presentation August 2024	Aug. 09	PU
Glaukos : Q2 2024 Earnings Transcript	Aug. 02	PU
Glaukos: Q2 Earnings Snapshot	Jul. 31	AQ

Trackinsight: Les investisseurs quittent les ETF sur l’innovation médicale	22-02-21
Akorn : Les valeurs à suivre à Wall Street	17-04-10

1 day	+0.72%
1 week	-3.44%
Current month	-3.44%
1 month	+7.32%
3 months	+13.49%
6 months	+47.82%
Current year	+62.64%

Director	Title	Age	Since
Thomas Burns CEO	Chief Executive Officer	63	00-12-31
Alex Thurman DFI	Director of Finance/CFO	54	16-06-30
Joseph Gilliam PSD	President	48	17-05-04

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GLAUKOS CORPORATION	+0.72%	-3.44%	+73.81%	+125.38%	7.1B
STRYKER CORPORATION	+0.26%	-0.42%	+23.96%	+28.14%	137B
SMITH & NEPHEW PLC	+0.54%	+3.61%	+12.97%	-11.36%	13.74B
INSPIRE MEDICAL SYSTEMS, INC.	-0.19%	+9.49%	-12.32%	-16.90%	5.87B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-2.72%	-5.65%	-55.52%	-65.40%	5.81B
AXONICS, INC.	-0.01%	-0.48%	+18.41%	-11.59%	3.52B
ENOVIS CORPORATION	+0.77%	-6.78%	-19.62%	-69.30%	2.43B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-0.43%	-0.89%	-23.94%	-43.67%	1.9B
DOUBLE MEDICAL TECHNOLOGY INC.	-1.74%	-0.53%	-18.04%	-49.36%	1.42B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-1.98%	-6.61%	-32.01%	-52.87%	1.4B
Average	-0.48%	+0.03%	-3.23%	-16.69%	18B
Weighted average by Cap.	+0.15%	-0.10%	+19.37%	+20.39%

Manager	Title	Age	Since
Thomas Burns CEO	Chief Executive Officer	63	00-12-31
David Hoffmeister BRD	Director/Board Member	69	14-06-30
Aimee Weisner BRD	Director/Board Member	55	14-06-30

	2024 *	2025 *
Net sales	374M	465M
Net income	-143M	-84.51M
Net Debt	180M	185M